Producer
B. Braun Medical
Second largest US IV fluid manufacturer, holding approximately 23% of the US market. Has invested over $1 billion across three US manufacturing sites since 2019. Operates facilities in Irvine CA, Daytona Beach FL, and Allentown PA. Produces non-PVC/non-DEHP IV bag products.
1
Inputs supplied
1
Goods downstream
2
Facilities
0
Stories
What they make
1 input B. Braun Medical supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something B. Braun Medical makes, pick one to see the full supply chain.
Where they make it
2 facilities
Daytona Beach IV Solutions Facility →
USFlorida · manufacturing
New B. Braun IV solutions manufacturing plant and distribution center in Daytona Beach, FL. Received FDA approval February 2022. Produces 0.9% sodium chloride (normal saline) for injection. Ramping output as part of post-Helene shortage response. Narrowly avoided damage when Hurricane Milton (October 2024) tracked north of the facility.
Irvine IV Fluids Manufacturing Facility →
USCalifornia · manufacturing
B. Braun's primary US west coast IV solutions plant, operating since 1974 (acquired from McGaw Medical). Expanded capacity by 20% in late 2024 during post-Helene shortage. Serves western US hospital market.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
IV Fluids & Infusion Therapy (US ~23% market share)
40%Renal Care / Dialysis (Avitum)
25%Hospital Products (Surgical, Pain, Infection Control)
35%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2023
B. Braun manufactures both IV fluids (for acute hospital patients) and dialysis solutions (for chronic kidney disease patients) from the same pharmaceutical-grade raw material base (ultrapure water, pharmaceutical NaCl, dextrose, electrolytes), but the patient populations and policy dependencies are completely different: IV fluid patients are acute (surgery, emergency, trauma, cancer infusion) — demand spikes with disasters, pandemics, and surgical volumes; dialysis solution patients are chronic — 550,000 US patients require ongoing treatment 3 times/week for life, with no option to delay. The US IV fluid market saw critical shortages after Hurricane Maria (2017 destroyed Baxter's Puerto Rico plant) and during COVID (supply chain disruptions). A shortage at B. Braun's Irvine plant simultaneously affects surgical ORs AND thousands of dialysis clinic patients whose treatment cannot be deferred. The non-PVC/non-DEHP Excel bag product line — a clinical differentiation — also creates a supply structure where B. Braun is the only or primary source for specific non-PVC IV bag formats used in pediatric and oncology applications that specifically avoid PVC plasticizers.
B. Braun Medical Inc. ↗Origin2023
B. Braun Melsungen AG was founded in 1839 by Julius Wilhelm Braun as a pharmacy in Melsungen, Hesse, Germany — a small town on the Fulda River in central Germany that predated the German nation-state itself (German unification 1871). Braun's pharmacy compounded medications and produced basic surgical supplies at a time when commercial pharmaceutical and medical device manufacturing did not exist. The company has remained family-owned since its 1839 founding — through two World Wars, the partition of Germany, and reunification — operating continuously from the same Melsungen headquarters. By 2023, B. Braun was generating approximately EUR 8.5 billion in annual revenue with 65,000+ employees globally while remaining a private, family-controlled German company. The family ownership structure — rare for a company of this size and age — reflects a deliberate choice to avoid IPO and external investor pressure, which B. Braun management has publicly cited as enabling long-term capital allocation decisions (such as the USD 1B+ US manufacturing investment announced after COVID supply chain disruptions).
B. Braun Melsungen AG ↗Capacity2019
B. Braun Medical invested over $1 billion across three US facilities between 2019 and 2024 specifically to prevent future IV fluid shortages — a direct response to the 2017 Hurricane Maria crisis. The investment tripled its US production footprint. Yet even with this expansion, B. Braun holds only 23% of the US IV fluid market vs. Baxter's 60%, leaving the market structure critically dependent on a single dominant supplier.
BioPharma Dive ↗